{"nctId":"NCT05144945","briefTitle":"Study Describing the Immunogenicity and Safety of Quadrivalent Recombinant Influenza Vaccine (RIV4) Versus a Licensed Quadrivalent-inactivated Influenza Vaccine (IIV4) (Fluarix® Quadrivalent) in Participants 18 Years of Age and Older in South Korea","startDateStruct":{"date":"2021-12-07","type":"ACTUAL"},"conditions":["Influenza (Healthy Volunteers)"],"count":301,"armGroups":[{"label":"Group 1: Quadrivalent Recombinant Influenza Vaccine (RIV4)","type":"EXPERIMENTAL","interventionNames":["Biological: Quadrivalent Recombinant Influenza Vaccine (RIV4)"]},{"label":"Group 2: Quadrivalent-inactivated Influenza Vaccine (IIV4)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: Quadrivalent inactivated influenza vaccine (IIV4)"]}],"interventions":[{"name":"Quadrivalent Recombinant Influenza Vaccine (RIV4)","otherNames":[]},{"name":"Quadrivalent inactivated influenza vaccine (IIV4)","otherNames":["Fluarix®"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Aged \\>=18 years on the day of inclusion.\n* Participants who were overtly healthy as determined by medical evaluation including medical history, physical examination.\n* Able to attend all scheduled visits and complied with all study procedures.\n* Informed consent form was signed and dated.\n* A female participant was eligible to participate if she was not pregnant or breastfeeding and one of the following conditions applies:\n\nWas of non-childbearing potential. To be considered of non-childbearing potential, a female must be postmenopausal for at least 1 year, or surgically sterile OR Was of childbearing potential and agreed to use an effective contraceptive method or abstinence from at least 4 weeks prior to the study intervention administration until at least 4 weeks after study intervention administration.\n\nA female participant of childbearing potential must had a negative highly sensitive pregnancy test (urine) before the first dose of study intervention.\n\nExclusion Criteria:\n\nParticipants were excluded from the study if any of the following criteria applied:\n\n* Participation at the time of study enrollment, or in the 6 months preceding the study vaccination, or planned participation during the present study period in another clinical study investigating involving an Investigational Medical Product (IMP) (vaccine, drug), medical device, or medical procedure or in any other type of medical research.\n* Receipt of any vaccine in the 4 weeks (28 days) preceding the study vaccination or planned receipt of any vaccine prior to Visit 2.\n* Previous vaccination against influenza (in the preceding 6 months) with either the study vaccine or another vaccine.\n* Receipt of immune globulins, blood, or blood-derived products in the past 3 months.\n* Known or suspected abnormal immune function: immunosuppression, suspected congenital or acquired immunodeficiency based on medical history and physical examination, or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy, or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).\n* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccines used in the study or to a vaccine containing any of the same substances.\n* Thrombocytopenia or bleeding disorder, contraindicating IM vaccination based on the Investigator's judgment.\n* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.\n* Current alcohol abuse or drug addiction that in the opinion of the Investigator might interfere with the study conduct or completion.\n* Chronic illness that, in the opinion of the Investigator, was at a stage where it might interfere with trial conduct or completion (Chronic illness may include, but is not limited to, cardiac disorders, renal disorders, auto-immune disorders, diabetes, psychiatric disorders, or chronic infection).\n* Moderate or severe acute illness/infection (according to Investigator judgment) on the day of vaccination or febrile illness (temperature \\>=38.0°C). A prospective participant should not be included in the study until the condition had resolved or the febrile event had subsided.\n* Personal or family history of Guillain-Barré syndrome.\n* Neoplastic disease or any hematologic malignancy (except localized skin or prostate cancer that was stable at the time of vaccination in the absence of therapy and participants who had a history of neoplastic disease and had been disease-free for \\>= 5 years).\n* Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (i.e., parent, spouse) of the Investigator or employee with direct involvement in the proposed study.\n\nThe above information was not intended to contain all considerations relevant to a potential participation in a clinical trial.","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 1- Per Protocol Analysis Set (PPAS)","description":"GMTs of anti-influenza antibodies were measured using hemagglutination inhibition (HAI) assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata lineages. Titers were expressed in terms of 1/dilution.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"30.8","spread":null},{"groupId":"OG001","value":"38.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.1","spread":null},{"groupId":"OG001","value":"47.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"109","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"237","spread":null},{"groupId":"OG001","value":"262","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 1- Full Analysis Set (FAS)","description":"GMTs of anti-influenza antibodies were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata lineages. Titers were expressed in terms of 1/dilution.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"29.8","spread":null},{"groupId":"OG001","value":"38.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","spread":null},{"groupId":"OG001","value":"47.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"104","spread":null},{"groupId":"OG001","value":"103","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"239","spread":null},{"groupId":"OG001","value":"259","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 29- PPAS","description":"GMTs of anti-influenza antibodies were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata lineages. Titers were expressed in terms of 1/dilution.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"961","spread":null},{"groupId":"OG001","value":"868","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"643","spread":null},{"groupId":"OG001","value":"378","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"646","spread":null},{"groupId":"OG001","value":"490","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1268","spread":null},{"groupId":"OG001","value":"897","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Titers (GMTs) of Influenza Vaccine Antibodies at Day 29- FAS","description":"GMTs of anti-influenza antibodies were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata lineages. Titers were expressed in terms of 1/dilution.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"955","spread":null},{"groupId":"OG001","value":"863","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"649","spread":null},{"groupId":"OG001","value":"379","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"640","spread":null},{"groupId":"OG001","value":"486","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1268","spread":null},{"groupId":"OG001","value":"899","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Fold-rise (GMFR) for Influenza Vaccine Antibodies-PPAS","description":"GMTs of anti-influenza antibodies were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata lineages. GMFR were calculated as the ratio of GMTs post-vaccination (on Day 29) and pre-vaccination (on Day 1).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"31.2","spread":null},{"groupId":"OG001","value":"22.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.8","spread":null},{"groupId":"OG001","value":"7.96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.95","spread":null},{"groupId":"OG001","value":"4.70","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.35","spread":null},{"groupId":"OG001","value":"3.42","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Fold-rise (GMFR) for Influenza Vaccine Antibodies-FAS","description":"GMTs of anti-influenza antibodies were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata lineages. GMFR were calculated as the ratio of GMTs post-vaccination (on Day 29) and pre-vaccination (on Day 1).","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"32.0","spread":null},{"groupId":"OG001","value":"22.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.2","spread":null},{"groupId":"OG001","value":"8.04","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.14","spread":null},{"groupId":"OG001","value":"4.74","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.31","spread":null},{"groupId":"OG001","value":"3.47","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Seroconversion Against Influenza Vaccine Antibodies-PPAS","description":"Anti-influenza antibodies were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata lineages. Seroconversion was defined as either a pre-vaccination titer less than (\\<) 1:10 (1/dilution) and a post-vaccination titer \\>=1:40 (1/dilution) or a pre-vaccination titer \\>= 1:10 (1/dilution) and a \\>= four-fold increase in post-vaccination titer at Day 29.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"95.9","spread":null},{"groupId":"OG001","value":"92.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.3","spread":null},{"groupId":"OG001","value":"74.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.1","spread":null},{"groupId":"OG001","value":"56.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.0","spread":null},{"groupId":"OG001","value":"47.3","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Seroconversion Against Influenza Vaccine Antibodies-FAS","description":"Anti-influenza antibodies were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata lineages. Seroconversion was defined as either a pre-vaccination titer less than (\\<) 1:10 (1/dilution) and a post-vaccination titer \\>=1:40 (1/dilution) or a pre-vaccination titer \\>= 1:10 (1/dilution) and a \\>= four-fold increase in post-vaccination titer at Day 29.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"92.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.6","spread":null},{"groupId":"OG001","value":"74.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"73.8","spread":null},{"groupId":"OG001","value":"56.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67.8","spread":null},{"groupId":"OG001","value":"47.7","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Antibody Titers Greater Than or Equal to (>=) 40 (1/Dilution) Against Influenza Vaccine Antibodies-PPAS","description":"Antibody titers were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata lineages. Percentage of participants with antibody titers \\>=40 (1/dilution) against influenza vaccine antibodies at Day 1 and Day 29 were reported in this outcome measure.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.7","spread":null},{"groupId":"OG001","value":"58.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.7","spread":null},{"groupId":"OG001","value":"65.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"82.8","spread":null},{"groupId":"OG001","value":"82.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.7","spread":null},{"groupId":"OG001","value":"94.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6","spread":null},{"groupId":"OG001","value":"99.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"99.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Antibody Titers >=40 (1/Dilution) Against Influenza Vaccine Antibodies-FAS","description":"Antibody titers were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata lineages. Percentage of participants with antibody titers \\>=40 (1/dilution) against influenza vaccine antibodies at Day 1 and Day 29 were reported in this outcome measure.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"51.0","spread":null},{"groupId":"OG001","value":"57.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"69.1","spread":null},{"groupId":"OG001","value":"64.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81.9","spread":null},{"groupId":"OG001","value":"82.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"89.9","spread":null},{"groupId":"OG001","value":"94.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"99.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"99.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.3","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Detectable Antibody Titers >= 10 (1/Dilution) Against Influenza Vaccine Antibodies- PPAS","description":"Antibody titers were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata lineages. Percentage of participants with antibody titers \\>=10 (1/dilution) against influenza vaccine antibodies at Day 1 and Day 29 were reported in this outcome measure.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"82.1","spread":null},{"groupId":"OG001","value":"90.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"91.0","spread":null},{"groupId":"OG001","value":"93.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.6","spread":null},{"groupId":"OG001","value":"96.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.6","spread":null},{"groupId":"OG001","value":"99.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With Detectable Antibody Titers >= 10 (1/Dilution) Against Influenza Vaccine Antibodies- FAS","description":"Antibody titers were measured using HAI assay for 4 influenza virus strains: A/H1N1, A/H3N2, B/Victoria, and B/Yamagata lineages. Percentage of participants with antibody titers \\>=10 (1/dilution) against influenza vaccine antibodies at Day 1 and Day 29 were reported in this outcome measure.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"81.2","spread":null},{"groupId":"OG001","value":"90.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"90.6","spread":null},{"groupId":"OG001","value":"93.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.0","spread":null},{"groupId":"OG001","value":"96.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"96.6","spread":null},{"groupId":"OG001","value":"99.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"100","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Immediate Unsolicited Adverse Events (AEs)","description":"An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product and which did not had any casual relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the case report form (CRF) in terms of diagnosis and/or onset window post-vaccination. All participants were observed for 30 minutes after vaccination, and any unsolicited AEs occurred during that time were recorded as immediate unsolicited AEs in the CRF.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Solicited Systemic Reactions","description":"A solicited reaction was an expected adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the CRF and considered as related to the study intervention administered. Solicited systemic reactions included fever, headache, malaise, myalgia, shivering, fatigue, nausea, and arthralgia.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"21","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50","spread":null},{"groupId":"OG001","value":"49","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"64","spread":null},{"groupId":"OG001","value":"64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7","spread":null},{"groupId":"OG001","value":"6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12","spread":null},{"groupId":"OG001","value":"16","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Solicited Injection Site Reactions","description":"A solicited reaction was an expected adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) prelisted (i.e., solicited) in the CRF and considered as related to the study intervention administered. Solicited injection site reactions included pain, erythema, swelling, induration, bruising and tenderness.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"77","spread":null},{"groupId":"OG001","value":"83","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"34","spread":null},{"groupId":"OG001","value":"21","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Unsolicited Adverse Events (AEs)","description":"An AE was any untoward medical occurrence in a clinical investigation participant administered a medicinal product and which did not had any casual relationship with the treatment. An unsolicited AE was an observed AE that did not fulfill the conditions prelisted in the CRF in terms of diagnosis and/or onset window post-vaccination.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16","spread":null},{"groupId":"OG001","value":"13","spread":null}]}]}]},{"type":"PRIMARY","title":"Number of Participants Reporting Serious Adverse Events (SAEs) And Adverse Events of Special Interest (AESI)","description":"A SAE was any untoward medical occurrence that at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event. A SAE which caused death of the participant was considered as fatal SAE. An AESIs were defined as one of scientific and medical concern specific to the Sponsor's study intervention, events for which ongoing monitoring and rapid communication by the investigator to the sponsor was done.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":149},"commonTop":["Injection Site Pain","Myalgia","Malaise","Fatigue","Headache"]}}}